公开(公告)号：US20240415832A1

公开(公告)日：2024-12-19

申请号：US18703145

申请日：2022-10-14

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng LI ,  Allen A. FIENBERG ,  Gretchen SNYDER ,  Robert E. DAVIS

IPC: A61K31/4985 ,  A61P25/36

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment for the treatment and/or prevention of fentanyl-analog induced overdose and related sequelae.

公开(公告)号：US20240207259A1

公开(公告)日：2024-06-27

申请号：US18596349

申请日：2024-03-05

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng LI ,  Robert DAVIS

IPC: A61K31/4985 ,  A61K9/00 ,  A61K9/16 ,  A61K9/48

CPC classification number: A61K31/4985 ,  A61K9/0053 ,  A61K9/16 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4891

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

公开(公告)号：US20240165111A1

公开(公告)日：2024-05-23

申请号：US18502460

申请日：2023-11-06

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Wei YAO ,  Peng LI ,  Robert DAVIS ,  Sharon MATES ,  Kimberly VANOVER ,  Gretchen SNYDER

IPC: A61K31/4985 ,  A61K9/00 ,  A61K9/16 ,  A61K31/445 ,  A61K45/00 ,  A61K45/06 ,  A61P25/00 ,  C07D241/40 ,  C07D471/16

CPC classification number: A61K31/4985 ,  A61K9/0019 ,  A61K9/16 ,  A61K31/445 ,  A61K45/00 ,  A61K45/06 ,  A61P25/00 ,  C07D241/40 ,  C07D471/16

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine Di and D2 receptor signaling system, and/or the wopioid receptor.

公开(公告)号：US20240122924A1

公开(公告)日：2024-04-18

申请号：US18518436

申请日：2023-11-22

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Sophie DUTHEIL ,  Gretchen SNYDER ,  Peng LI ,  Robert E. DAVIS

IPC: A61K31/4985 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P29/00

CPC classification number: A61K31/4985 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P29/00

Abstract: The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.

公开(公告)号：US20240033262A1

公开(公告)日：2024-02-01

申请号：US18478482

申请日：2023-09-29

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng LI ,  Robert DAVIS

IPC: A61K31/4985 ,  A61K9/48 ,  A61K9/00 ,  A61K9/16

CPC classification number: A61K31/4985 ,  A61K9/4858 ,  A61K9/4825 ,  A61K9/0053 ,  A61K9/4891 ,  A61K9/16 ,  A61K9/485

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

公开(公告)号：US20240002403A1

公开(公告)日：2024-01-04

申请号：US18240951

申请日：2023-08-31

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng LI ,  Robert E DAVIS ,  Kimberly Vanover

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I,




and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

公开(公告)号：US20230416300A1

公开(公告)日：2023-12-28

申请号：US18042103

申请日：2021-08-20

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng LI ,  Robert E. DAVIS ,  Yupu QIAO

IPC: C07J43/00

CPC classification number: C07J43/003 ,  C07B2200/05

Abstract: The invention relates to particular substituted (3α,5β-3-hydroxy-pregnan-20-ones, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.

公开(公告)号：US20230346787A1

公开(公告)日：2023-11-02

申请号：US18339956

申请日：2023-06-22

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Wei YAO ,  Peng LI

IPC: A61K31/519 ,  A61K45/06 ,  A61P25/24 ,  A61K31/4985 ,  C07D471/14 ,  A61P25/00 ,  A61P25/28 ,  A61P25/18

CPC classification number: A61K31/519 ,  A61K31/4985 ,  A61K45/06 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D471/14

Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

公开(公告)号：US20220356187A1

公开(公告)日：2022-11-10

申请号：US17753472

申请日：2020-09-03

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng LI ,  Robert DAVIS

IPC: C07D487/14 ,  A61K38/00

Abstract: The present invention relates to PDE1 inhibitory compounds useful in the treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as, among others, Parkinson's disease, depression, narcolepsy, psychosis, damage to cognitive function, e.g., in schizophrenia, or disorders that may be ameliorated through enhanced progesterone-signaling pathway, as well as their use as pharmaceuticals and pharmaceutical compositions comprising them. Methods of making and methods of use related to such compounds are further described.

公开(公告)号：US20220332716A1

公开(公告)日：2022-10-20

申请号：US17808836

申请日：2022-06-24

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： John Charles TOMESCH ,  Peng LI ,  Wei YAO ,  Qiang ZHANG ,  James David BEARD ,  Andrew S. THOMPSON ,  Hua CHENG ,  Lawrence P. WENNOGLE

IPC: C07D471/16 ,  C07D471/04

Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycl fused gamma-carbolines.